Infectious Diseases (all articles)
M-A | Efficacy and safety of COVID-19 inactivated vaccine.
1 Dec, 2022 | 14:00h | UTCEfficacy and safety of COVID-19 inactivated vaccine: A meta-analysis – Frontiers in Medicine
Collection of Cochrane evidence on diagnosing tuberculosis.
1 Dec, 2022 | 13:56h | UTCCollection of Cochrane evidence on diagnosing tuberculosis – Cochrane Library
RCT | Medical masks vs. N95 respirators for preventing COVID-19 among health care workers.
30 Nov, 2022 | 13:52h | UTC
Commentary on Twitter
A randomized trial of medical masks vs N95s in health care workers to prevent Covid https://t.co/CSJkFLE15z
—It's woefully underpowered but ruled out a doubling of hazard for use of medical masks
—In 3 of the 4 countries there was less risk with N95s (p=NS) pic.twitter.com/B7iBvT1J9B— Eric Topol (@EricTopol) November 28, 2022
ACP Guidance | Outpatient treatment of confirmed COVID-19.
30 Nov, 2022 | 13:54h | UTCCommentary: New ACP living practice points, mortality data on COVID-19 – ACP Internist
Cohort Study | Acute and postacute sequelae associated with SARS-CoV-2 reinfection.
30 Nov, 2022 | 13:42h | UTCAcute and postacute sequelae associated with SARS-CoV-2 reinfection – Nature Medicine
News Release: Repeat COVID-19 infections increase risk of organ failure, death – Washington University School of Medicine
Commentary: SARS-CoV-2 Reinfection Ups Risks for Death, Hospitalization – HealthDay
Joint consensus statement on the vaccination of adult and pediatric hematopoietic stem cell transplant recipients.
30 Nov, 2022 | 13:39h | UTC
German guideline on diverticular disease/diverticulitis.
30 Nov, 2022 | 13:41h | UTCEditorial: New German guidelines for the management of diverticulitis – UEG Journal
Related:
Systematic Review: Antibiotics for uncomplicated diverticulitis.
Efficacy and Safety of Non-Antibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre, Randomised, Open-Label, Non-Inferiority Trial – Annals of Surgery (link to abstract – $ for full-text)
Elective surgical management of diverticulitis – Current Problems in Surgery
Management of Colonic Diverticulitis – Agency for Healthcare Research and Quality
WHO renames “monkeypox” as “mpox” to help destigmatize the disease.
29 Nov, 2022 | 14:27h | UTCWHO recommends new name for monkeypox disease – World Health Organization
Commentaries:
WHO to phase out the name ‘monkeypox’ for ‘mpox’ – STAT
WHO renames monkeypox as mpox, citing racist stigma – NPR
The Future of Monkeypox – The Atlantic
Monkeypox given new name by global health experts – BBC
Monkeypox to be renamed mpox to avoid stigma, says WHO – The Guardian
Commentary on Twitter (thread – click for more)
Following consultations, WHO will begin using a new term for “#monkeypox” disease: '#mpox'.
Both names will be used simultaneously for one year while 'monkeypox' is phased out https://t.co/VT9DAdYrGY pic.twitter.com/Ae6zgkefPI— World Health Organization (WHO) (@WHO) November 28, 2022
WHO Global tuberculosis report 2022.
29 Nov, 2022 | 14:25h | UTCGlobal tuberculosis report 2022 – World Health Organization
News Release: Tuberculosis deaths and disease increase during the COVID-19 pandemic – World Health Organization
Video Summary: WHO Global Tuberculosis Report 2022: Key findings and messages – World Health Organization
Commentary on Twitter (thread – click for more)
? WHO 2022 Global TB report ?
For the first time in many years, an increase has been reported in the number of people falling ill with #tuberculosis (TB) and drug-resistant TB.
? https://t.co/AvVFJ6j1E5 pic.twitter.com/dPywHXZ6ND
— World Health Organization (WHO) (@WHO) October 27, 2022
Study shows Omicron sublineage BQ.1.1 is resistant to all monoclonal antibodies.
29 Nov, 2022 | 14:16h | UTCOmicron sublineage BQ.1.1 resistance to monoclonal antibodies – The Lancet Infectious Diseases
Commentaries:
Omicron variant BQ.1.1 found to be resistant to all monoclonal antibody treatments – MedicalXpress
Related: BQ.1 and BQ.1.1 are now the dominant COVID variants. What does that mean? – MedicalXpress
Commentary on Twitter
The BQ.1.1 variant, as compared with many of the other new variants, is resistant to all clinically used monoclonal antibodies.
BQ.1/BQ.1.1 are now the dominant variants in the United Stateshttps://t.co/PCFPSGF2uy @TheLancetInfDis pic.twitter.com/dHucxoGokC— Eric Topol (@EricTopol) November 19, 2022
Cohort Study | Impact of the trimester of diagnosis on COVID-19 disease progression in pregnancy.
29 Nov, 2022 | 14:18h | UTCExamining the impact of trimester of diagnosis on COVID-19 disease progression in pregnancy – American Journal of Obstetrics & Gynecology MFM (free for a limited period)
News Release: Risk of severe COVID-19 symptoms remains throughout pregnancy, study finds – UT Southwestern Medical Center
Commentary on Twitter
Aug 20: Examining impact of trimester of diagnosis on #COVID19 disease progression in #pregnancy: Moderate, severe, or critical illness develops in almost 10% of pregnant patients; frequency of disease progression does not differ by trimester @ajogmfm https://t.co/hnF8QxmE2k!
— All Source Pregnancy (@PregnancyAll) August 20, 2022
Liposomal amphotericin B — Past, present and future.
29 Nov, 2022 | 14:03h | UTCLiposomal amphotericin B—the past – Journal of Antimicrobial Chemotherapy
Liposomal amphotericin B—the present – Journal of Antimicrobial Chemotherapy
Liposomal amphotericin B—the future – Journal of Antimicrobial Chemotherapy
RCT | Rezafungin vs. caspofungin for treatment of candidaemia and invasive candidiasis.
29 Nov, 2022 | 13:54h | UTCRezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial – The Lancet (link to abstract – $ for full-text)
Review | Infectious complications of abortion.
29 Nov, 2022 | 13:56h | UTCInfectious Complications of Abortion – Open Forum Infectious Diseases
Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
27 Nov, 2022 | 22:30h | UTCCommentary: Report highlights the deadly impact of bacterial infections – CIDRAP
Commentary on Twitter (thread – click for more)
1 in 8 deaths are due to the deadliest bacterial pathogens in the world, making them the second-leading cause of death behind ischemic heart disease @TheLancethttps://t.co/PEPYvxRcqV pic.twitter.com/S6odJodsVj
— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) November 21, 2022
Seminar | Monkeypox.
27 Nov, 2022 | 22:29h | UTCCommentaries:
Study shows there is substantial monkeypox transmission before symptoms appear.
Monkeypox – New England Journal of Medicine
Monkeypox: disease epidemiology, host immunity and clinical interventions.
Monkeypox: A clinical update for paediatricians – Journal of Pediatrics and Child Health
CDC Report | Epidemiologic and clinical characteristics of Monkeypox cases in the US.
Update on the Monkeypox Outbreak – JAMA
WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch
Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases
Commentary on Twitter
Seminar: Monkeypox
In light of the 2022 global outbreak, @oriolmitja and colleagues provide an overview of epidemiology, clinical presentation, treatment, prevention, and more.
? https://t.co/gB0fcokA8D pic.twitter.com/Db3ZsU4ykt
— The Lancet (@TheLancet) November 22, 2022
RCT | Rectal culture-based vs. empirical antibiotic prophylaxis to prevent infections in men undergoing transrectal prostate biopsy.
27 Nov, 2022 | 22:28h | UTCRectal culture-based versus empirical antibiotic prophylaxis to prevent infectious complications in men undergoing transrectal prostate biopsy: a randomized, non-blinded multicenter trial – Clinical Infectious Diseases (link to abstract – $ for full-text)
Commentary on Twitter
RCT of rectal culture-based vs. empiric antibiotic prophylaxis to prevent infectious complications after transrectal prostate biopsy.
Potentially practice-changing study. Thoughts, @AshleyGWinter? @sigal_md Others? https://t.co/rJQusECapO @CIDJournal pic.twitter.com/94tBa2i1eN
— Paul Sax (@PaulSaxMD) November 24, 2022
Improving antimicrobial stewardship with penicillin allergy testing: a review of current practices and unmet needs.
27 Nov, 2022 | 22:25h | UTCRelated:
M-A: Most patients with allergy to Penicillin can be given Cefazolin
Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy
Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule
NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk
Global burden of Rabies in 204 countries and territories, from 1990 to 2019.
27 Nov, 2022 | 22:04h | UTC
M-A | Cardioprotective effects of influenza vaccination in patients with high risk of cardiovascular disease.
25 Nov, 2022 | 12:47h | UTCCardioprotective effects of influenza vaccination among patients with established cardiovascular disease or at high cardiovascular risk: a systematic review and meta-analysis – European Journal of Preventive Cardiology (free for a limited period)
Related:
RCT | Influenza vaccine to reduce adverse vascular events in patients with heart failure.
Study shows there is substantial monkeypox transmission before symptoms appear.
25 Nov, 2022 | 12:43h | UTCTransmission dynamics of monkeypox in the United Kingdom: contact tracing study – The BMJ
Editorial: The dynamics of monkeypox transmission – The BMJ
News Release: Evidence for “substantial” monkeypox transmission before symptoms – BMJ Newsroom
Commentaries:
Study finds evidence of ‘considerable’ presymptomatic spread of monkeypox – The Guardian
Review | Climate change and vectorborne diseases.
24 Nov, 2022 | 13:31h | UTCClimate Change and Vectorborne Diseases – New England Journal of Medicine
Commentary on Twitter
Warming temperatures and changes in precipitation associated with climate change are affecting the occurrence of vectorborne diseases. Effective, equitable strategies are needed for vector control and disease management. https://t.co/o1yUTkjs93 pic.twitter.com/4Qn4RRXBcL
— NEJM (@NEJM) November 23, 2022
Review | Care of the seriously ill patient with SARS-CoV-2.
24 Nov, 2022 | 13:26h | UTCCare of the Seriously Ill Patient with SARS-CoV-2 – Medical Clinics of North America
KDIGO 2022 Guideline for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease.
23 Nov, 2022 | 14:11h | UTCExecutive Summary: KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease – Kidney International
RCT | Treatment of early Lyme Disease with doxycycline for 7 days is noninferior to treatment for 14 days.
23 Nov, 2022 | 14:06h | UTCTreatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Commentary: Shorter Duration of Antibiotics Noninferior for Lyme Disease – JAMA (free for a limited period)
Commentary on Twitter
New research: Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trialhttps://t.co/8lktc4gxzG pic.twitter.com/mP2e0Kn7C5
— The Lancet Infectious Diseases (@TheLancetInfDis) October 7, 2022